Cyrus Harmon
July 22, 2020 08:10 AM EDT
Financing

Can ful­ly shut­ting down the es­tro­gen re­cep­tor make a dif­fer­ence in breast can­cer? Ole­ma scores $54M to find out in the clin­ic

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

Lan­theus culls late-stage Lil­ly-part­nered prostate can­cer ra­di­oli­gand

Te­va plans staff cuts as it com­mits to ac­cel­er­at­ing growth

Gilead re­veals plans to put an­oth­er $11B in­to US man­u­fac­tur­ing

Biotech stocks plunge and in­dus­try fig­ures left to won­der af­ter Prasad's FDA ap­point­ment

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times